# Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

> **NCT04307186** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 57 (actual)

## Conditions studied

- Central Nervous System Pathology

## Interventions

- **DRUG:** Gadoquatrane (BAY1747846)
- **DRUG:** Gadobutrol (Gadovist/Gadavist)

## Key facts

- **NCT ID:** NCT04307186
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2022-09-05
- **Final completion:** 2022-09-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04307186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04307186, "Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04307186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*